Doxorubicin Hydrochloride → Doxorubicin

HRID 1034378Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1034378
[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][C@@H:9]2[C:14]3=[C:15]([OH:32])[C:16]4[C:28](=[O:29])[C:27]5[C:22](=[CH:23][CH:24]=[CH:25][C:26]=5[O:30][CH3:31])[C:20](=[O:21])[C:17]=4[C:18]([OH:19])=[C:13]3[CH2:12][C@@:11]([OH:37])([C:33]([CH2:35][OH:36])=[O:34])[CH2:10]2)[CH2:5][C@H:4]([NH2:38])[C@@H:3]1[OH:39].Cl>CC(N(O)CCCCCNC(CCC(N(O)CCCCCNC(CCC(N(O)CCCCCN)=O)=O)=O)=O)=O.CS(O)(=O)=O>[CH3:1][C@@H:2]1[O:7][C@@H:6]([O:8][C@@H:9]2[C:14]3=[C:15]([OH:32])[C:16]4[C:28](=[O:29])[C:27]5[C:22](=[CH:23][CH:24]=[CH:25][C:26]=5[O:30][CH3:31])[C:20](=[O:21])[C:17]=4[C:18]([OH:19])=[C:13]3[CH2:12][C@@:11]([OH:37])([C:33]([CH2:35][OH:36])=[O:34])[CH2:10]2)[CH2:5][C@H:4]([NH2:38])[C@@H:3]1[OH:39]

Komponenten

3

Edukt 1

HCID 443939Doxorubicin Hydrochloride

Produkt 1

HCID 31703Doxorubicin

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 62881Deferoxamine MesylateLösungsmittel

Versuchsvorschrift

1 ml of a 10 mg/ml solution of doxorubicin HCl dissolved in saline-desferal was added to I ml of the liposome dispersion after the liposomes were gel filtrated on a Sephadex G-50 column. The mixture was incubated at room temperature for approximately 24 hours. The incubation was shorter for certain types of kinetic experiments. At the end of incubation period, the mixture was passed through a Dowex 50 WX-4 column to adsorb the free drug. The resin is able to adsorb as much as 1 mg of free doxorubicin in a 15 min time while the sequestered liposome incorporated remains with the liposomes. A column containing 1-2 g dry weight of the resin was sufficient to adsorb all unincorporated drug. To determine the ratio of incorporated drug to liposomal lipid., the phospholipid and doxorubicin concentration were determined as described previously.

Aufarbeitung

  1. additionwas added to I ml of the liposome dispersion after the liposomes
  2. filtrationfiltrated on a Sephadex G-50 column
  3. customin a 15 min
  4. additionA column containing 1-2 g
  5. customdry weight of the resin
  6. concentration, the phospholipid and doxorubicin concentration

Quellen und Nachweise

ORD-Eintrag
ord-b6425798170940428bd12f1d5331f419
Quelldatensatz
uspto-grants-1994_05
Patentnummer
US05316771

Notizen zur Reaktion

Wird geladen…